Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Dario Vignali
University of Pittsburgh at Pittsburgh, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tizona Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Vignali's conflict arises due to his interest as an inventor of the intellectual property being evaluated/developed in this bench and animal research, which St. Jude's Children's Research Hospital patented and optioned/licensed to Tizona Therapeutics. Dr. Vignali also consults for Tizona and has an ownership interest in the company.
Interleukin-35 and the tumor microenvironment
PROJECT NARRATIVE Regulatory T cells (Tregs) are potent inhibitors of anti-tumor immunity, but are also required for the maintenance of immune homeostasis. Consequently, Treg deletion is not a viable therapeutic strategy for the treatment of cancer and instead more targeted approaches are required that only impact Treg function in tumors. Interleukin-35 (IL35) represents a viable therapeutic target as its neutralization or genetic deletion limits tumor growth without inducing autoimmunity or inflammatory disease.
Filed on August 09, 2016.
Tell us what you know about Dario Vignali's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Dario Vignali filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Dario Vignali | University of Pittsburgh at Pittsburgh | Conflict of Interest | Tizona Therapeutics | $80,000 - $99,999 |
| Dario Vignali | University of Pittsburgh at Pittsburgh | Conflict of Interest | Tizona Therapeutics | $40,000 - $59,999 |
| Dario Vignali | University of Pittsburgh at Pittsburgh | Conflict of Interest | Bristol-Myers Squibb Company | $20,000 - $39,999 |
| Dario Vignali | University of Pittsburgh at Pittsburgh | Conflict of Interest | Bristol-Myers Squibb Company | $20,000 - $39,999 |
| Dario Vignali | University of Pittsburgh at Pittsburgh | Conflict of Interest | Merck | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.